



March 18, 2020

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Notice Pursuant to 18 V.S.A. § 4637


To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. ("Teva") submits this information pursuant to 18 V.S.A. § 4637(b). On March 16, 2020 Teva released the following prescription drug to the commercial market:

NDC #	Product	WAC	Commercial Launch Date
63459-0303-43	HERZUMA® (trastuzumab-pkrb) 150 MG / 50 ML	\$1,402.50	03/16/2020
63459-0305-47	HERZUMA® (trastuzumab-pkrb) 420 MG / 10 ML	\$3,927.00	03/16/2020

Teva provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this notice, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Sincerely,

DocuSigned by:

FB77687EB417471...

Jason Daly
SVP, US Market Access
Teva Pharmaceuticals USA, Inc.